What does it mean to our patients? Presenter: CF Otieno Affiliation: Department of Clinical Medicine and Therapeutics,UoN & KNH-Medicine.

Slides:

Advertisements

Similar presentations

Importance of early glycemic control in management of type 2 diabetes

Advertisements

Diabetes Overview Managing Diabetes in Primary Care.

BY Dr. Khaled Helmy Al Mahmora Chest Hospital BY Dr. Khaled Helmy Al Mahmora Chest Hospital Treatment Of Hypertension In Diabetes.

K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. The diabetic sub study of.

Benefits of intensive multiple risk factor intervention.

Introduction To The Alphabet Strategy And Evidence Based Medicine.

UKPDS Paper 36 Slides © University of Oxford Diabetes Trials Unit UKPDS slides are copyright and remain the property of the University of Oxford Diabetes.

UKPDS Paper 35 Slides © University of Oxford Diabetes Trials Unit

UKPDS Paper 81 Slides © University of Oxford Diabetes Trials Unit UKPDS slides are copyright and remain the property of the University of Oxford Diabetes.

Al-Fada AA & Bin Abdulrahman KA, King Saud University, Riyadh, Saudi Arabia Assessment of Care for Type 2 Diabetic Patients at the PHC Clinics of a Referral.

Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.

Canadian Diabetes Association 2013 Clinical Practice Guidelines Targets for Glycemic Control Chapter 8 S. Ali Imran, Rémi Rabasa-Lhoret, Stuart Ross.

Diabetic Microvascular Disease: The Role of Glycemic Control and the Impact on Public Health Robert E. Ratner, MD MedStar Research Institute Georgetown.

Clinical Issues in the Management of Non Communicable Diseases Dr Gyaneshwar Rao Colonial War Memorial Hospital Suva.

Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.

Microvascular complications Diabetes Outreach (August 2011)

Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.

Therapy of Type 2 Diabetes Mellitus: UPDATE

Rapid E clinical guidance in the management of Type 2 diabetes New Zealand Guidelines Group.

Adult Medical-Surgical Nursing Endocrine Module: Longterm Complications of Diabetes Mellitus.

ACUTE STROKE — Hypertension is a common problem in patients with both type 1 and type 2 diabetes but the time course in relation to the duration.

Joint Effects of Routine Blood Pressure Lowering and Intensive Glucose Control ADVANCE Adapted from EASD 2008.

Liberty Medical. Microvascular and Macrovascular.

PEBB Board Presentation Kaiser 2006 Quality Initiatives.

Effect of Hypertension and Dyslipidemia on glycemic control among Type 2 Diabetes patients in Thailand Dr. Mya Thandar Dr.PH. Batch 5 1.

1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.

Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.

FDA Endocrinologic and Metabolic Drugs Advisory Committee 1st June 2008 Rury Holman Clinical outcomes with anti-diabetic drugs: What we already know.

Can pharmacists improve outcomes in hypertensive patients? Sookaneknun P (1), Richards RME (2), Sanguansermsri J(1), Teerasut C (3) : (1)Faculty of Pharmacy,

Group 7 Burden of disease in Brazil. KEY HEALTH INDICATORS Years of life lost (YLLs): Years of life lost due to premature mortality. Years lived with.

Effect of Hypertension and Dyslipidemia on glycemic control among Type 2 Diabetes patients Dr. Mya Thandar.

The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.

Effect of Hypertension and Dyslipidemia on glycemic control among Type 2 Diabetes patients in Thailand Dr. Mya Thandar DrPH Batch 5 1.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015

Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.

ASCOT and Steno-2: Aggressive risk reduction benefits two different patient populations *Composite of CV death, nonfatal MI or stroke, revascularization,

UKHDS (UKPDS): UK Hypertension in Diabetes Study Purpose To determine whether tight control of blood pressure (aiming for BP

The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & Early DM Part 5 Stan Schwartz MD, FACP, FACE.

Baseline characteristics. Patient flow Completed Completed Perindopril Placebo Randomised Not randomised Registered.

Impact of Diabetes on Cardiovascular Risk C.Richard Conti M.D. MACC Oct 16,2004 GWICC Beijing, PRC.

Heterogeneity and Comparative Effectiveness: Implications for Studies, Reviews, and Policy David Atkins, MD, MPH Health Services Research and Development.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015

Complex Medical Patients Wayne Katon, MD.  Definition: Illnesses with high prevalence, high comorbidity and bidirectional adverse interactions Examples:

Diabetes and the Kidney Richard Kingston Department of Renal Medicine Kent and Canterbury Hospital.

The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.

Presentation Developed for the Academy of Managed Care Pharmacy

CoRPS Center of Research on Psychology in Somatic diseases Type D personality as a risk factor for adverse vascular outcomes in diabetes patients: A role.

IDF EUROPE GA MEETING MUNICH,2005 SURVEY ON DIABETES CARE IN EIGHT CENTRAL EASTERN EUROPEAN COUNTRIES (THE DEPAC STUDY)

The RAVE Study Renal Athersosclerotic Revascularization Evaluation Reference Tobe SW, Atri M, Perkins N, et al. Renal Athersosclerotic revascularization.

Circulation. 2014;129: Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy.

Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.

Preventive Measures Infection & Delayed Wound Healing Frequent dental visits to assess plaque control Risk assessment profiles to identify risk factors.

Dr John Cox Diabetes in Primary Care Conference Cork

Discontinuation of medication after nonfatal event: MI

DIABETES CARE IN AN ORTHOPAEDIC LED FOOT CLINIC

Alcohol, Other Drugs, and Health: Current Evidence July–August 2017

The IDEAL Study Reference

Copyright © 2007 American Medical Association. All rights reserved.

The Anglo Scandinavian Cardiac Outcomes Trial

First time a CETP inhibitor shows reduction of serious CV events

CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?

Nat. Rev. Nephrol. doi: /nrneph

National Diabetes Strategy

Developing and Using a Referral Network

GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?

Composite of complications including cardiovascular (CV): acute myocardial infarction, cardiac arrhythmia requiring medical treatment and heart failure;

The Clock is ticking for the world’s leaders

Ongoing statin therapy at hospitalization for acute myocardial infarction. Learnings for general practitioners. Ghena Shabana Specialist in Family Medicine.

Schematic overview of diabetes-associated microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular (cerebrovascular, coronary artery,

Prevalence of clinically significant microvascular (green) and clinically significant macrovascular (yellow) disease alone and combined microvascular and.

Presentation transcript:

What does it mean to our patients? Presenter: CF Otieno Affiliation: Department of Clinical Medicine and Therapeutics,UoN & KNH-Medicine

TYPE 2 DIABETES Progressive disease Well characterized... But-poorly controlled Broad treatment goals:- glycaemia,BP,LDL,Weight,Knowledge,Self management,HRQoL etc

RISK FACTORS OF COMPLICATIONS Microvascular Hyperglycaemia Genetics (Hypertension) Macrovascular Lipids Hypertension Genetics Age

COMPLICATION PROFILES AT KNH Microvascular Eye Neuropathy Nephropathy Microalbuminuria Macroalbuminuria ESRD

MACROVASCULAR COMPLICATIONS Cerebrovascular disease (Mwazo) Myocardial infarction (Nguchu) (STEMI/NSTEMI) Erectile dysfunction (Ngalyuka)

COMPOSITE COMPLICATIONS Renal disease Diabetic foot ulcer, 7.8%: (Diabetes) – Risk factors (The patient) – Knowledge, Attitude, Practice (The health unit) – Policy Foot-at-risk>33% (Mugambi E, et al)

RISK FACTOR PROFILE AT KNH Glycaemic control: <40% good control BP control – only 50% known HTN, out of these only 25% well controlled. Lipids - high LDL Adherence to treatment – POOR

REASONS FOR POOR CONTROL Provider factors: Knowledge, Attitude, Practices, etc System factors Policies, Medication access, Insulin access Patient factors Knowledge, Attitude, Practices, Socio-Economic Status Heterogeneous disease

CONSEQUENCES OF POOR CONTROL Enhanced complications ( at early age) Renal Cardiac Stroke Attenuated HRQoL Health resource consumption-hospitalization; dependance.

CAN WE STEM THE TIDE? Access to care: Policies Physical Quality of care and evaluation Clinical end-points Administrative end-points Risk stratification of patients? Address fatigue of care providers?

AREAS TO ADDRESS Health system adjustment: patient-focused decision- making Generate evidence:-longitudinal studies for outcomes; RCTs etc. Cost-related studies-effectiveness and benefit analysis MORTALITY reviews

In conclusion,.. We need to ask ourselves: Can we tell whether our patients are better off NOW than thirty years ago ? OR What ails our patients? What does the care we give mean to them ?

THANK YOU